Trial · NCT00452868
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
NCT00452868, Early phase 1, Completed, Wake Forest University Health Sciences; results first posted 2013-02-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain. Trials, record NCT00452868. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00452868
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
- NCT number
- NCT00452868
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
- Interventions
- Donepezil
- First posted
- 2007-03-28
- Last updated
- 2018-09-07
- Results first posted
- 2013-02-28
- Limitations and caveats
- small number (11) analyzed
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks | 24 weeks | Delis-Kaplan Executive Function System Tower Total Scaled Score, range is 1-19 with the higher score being a better outcome. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks | 24 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks | Donepezil | 10 | Standard Deviation 3 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Donepezil | 13 | |
| Overall Study | COMPLETED | Donepezil | 11 | |
| Overall Study | NOT COMPLETED | Donepezil | 2 |
Source ClinicalTrials.gov
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Donepezil | 6 | 11 | 6 |
| other | Diarrhea | Gastrointestinal disorders | Donepezil | 5 | 11 | 5 |
| other | Anorexia | General disorders | Donepezil | 5 | 11 | 5 |
| other | Incontinence, urinary | Renal and urinary disorders | Donepezil | 1 | 11 | 1 |
| other | Personality/behavioral | Psychiatric disorders | Donepezil | 1 | 11 | 1 |
| other | Dizziness | Ear and labyrinth disorders | Donepezil | 1 | 11 | 1 |
| other | Insomnia | Psychiatric disorders | Donepezil | 4 | 11 | 4 |
| other | Neurology | Nervous system disorders | Donepezil | 2 | 11 | 2 |
| other | Fatigue | General disorders | Donepezil | 10 | 11 | 10 |
| other | Pain: Head/headache | Nervous system disorders | Donepezil | 1 | 11 | 1 |
1 to 10 of 33Source ClinicalTrials.gov
See all 33 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Donepezil | ||
| Total, other adverse events | Donepezil | 11 | |
| Total, serious adverse events | Donepezil | 3 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA012197 | Cancer Center Support Grant | MESA, RUBEN A. | WAKE FOREST UNIVERSITY HEALTH SCIENCES | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00452868
GET https://conductscience.org/api/trials/v1/NCT00452868/events?page=2